Navigation Links
Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
Date:9/14/2010

pond to these treatments experience a clinical recurrence following cessation of antibiotic administration.

Primary risk factors for CDI include broad-spectrum antibiotic use (such as cephalosporins and fluoroquinolones), advanced age (over 65) and exposure to emerging hyper-virulent strains (BI/NAP1/027, 078, 001) of C. difficile. Increasing incidence, higher treatment failures and recurrence with current therapies have resulted in greater awareness and concern of CDI among medical professionals and public health officials.

About FidaxomicinFidaxomicin is the first in a new class of antibiotics called macrocycles, which inhibit the bacterial enzyme RNA polymerase, resulting in the death of C. difficile. The narrow-spectrum profile of fidaxomicin may eradicate C. difficile selectively with minimal disruption to the normal intestinal flora, while the alternative antibiotics to treat CDI, metronidazole and vancomycin, disrupt the flora. Fidaxomicin may facilitate the return of normal physiological conditions in the colon which may be responsible for reducing CDI recurrence.

About Optimer PharmaceuticalsOptimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing hospital specialty products to treat serious infections and address unmet medical needs. Optimer has two anti-infective product candidates in development. Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI). Optimer has completed two Phase 3 trials of fidaxomicin for the treatment of CDI, demonstrating that fidaxomicin was statistically superior to vancomycin in global cure rate (defined as cure with no recurrence within four weeks of completing therapy) as well as statistically superior in reducing recurrences of CDI by up to 50% when compared with vancomycin, the only FDA approved product for CDI. Optimer has also successf
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
2. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
3. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
4. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
5. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
6. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
7. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
8. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
9. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
10. Stemedica Announces Completion of Clinical Stem Cell Master Bank
11. DATATRAK International, Inc. Announces Initial Equity Research Coverage by Zacks Investment Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... (PRWEB) March 26, 2015 WriteResult, a ... with researchers from Yale University’s School of Public Health ... study participants during a 4 month-long project. The goal ... providing low income families with free access to fresh ... and diet-related health concerns like high blood pressure, diabetes ...
(Date:3/25/2015)... 2015 Agnition announced today that it ... Farmer, airing for the first time at 7:30 a.m. ... Farmer will explore the extremely important role soil microbes ... a patented Microbial Catalyst™ technology that enhances soil and ... segment will air again on April 28. , A ...
(Date:3/25/2015)... ROCKVILLE, Md. , March 25, 2015 ... for the Vaccine Industry Excellence (ViE) Award "Best Clinical ... second consecutive year that Optimal has been selected as ... World Vaccine Congress, receiving a "Highly Recommended" distinction in ... generate recognition of the efforts, accomplishments, and positive contributions ...
(Date:3/25/2015)...  S&P Capital IQ (MHFI) announced today that ... on Abattis Bioceuticals Corp . ... specialty biotechnology company with capabilities through its wholly ... ingredients, bio-similar compounds, patented equipment and consulting services ... . The company seeks to capitalize on ...
Breaking Biology Technology:Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 2Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 3Agnition to be Featured In Upcoming Episode of American Farmer on RFD-TV 2Optimal Research Nominated 2015 Vaccine Industry Excellence (ViE) Award 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 5
... YORK, April 7, 2008 /Xinhua-PRNewswire-FirstCall/ -- China YCT,International ... that,its wholly owned subsidiary, Shandong Spring Pharmaceutical Co., ... Shandong Yong Chun Tang,Bioengineering Co. Ltd., effective as ... Spring Pharmaceutical will manage the operations of,Shandong Yong ...
... has found that the,Replikin Count(TM) of the H1N1 strain ... its highest level since the 1918 H1N1,pandemic (p value ... particular,influenza strain, indicating rapid replication of the virus, is ... outbreak of the specific,strain. The current increase appears to ...
... joins founding management team to direct ITI,s Center for ... Critical Path ... Tolerance,Institute Inc., (ITI) today announced that Aaron B. Kantor, Ph.D. has,joined ... A. Matis, M.D., President and Chief Executive Officer. Prior to,joining ITI, ...
Cached Biology Technology:China YCT International Group, Inc. Announces Entrusted Management Agreement With Its Primary Supplier 2China YCT International Group, Inc. Announces Entrusted Management Agreement With Its Primary Supplier 3H1N1 Influenza Virus With Highest Replikin Count(TM) Since the 1918 Pandemic Identified in the U.S. and Austria 2Immune Tolerance Institute Appoints Aaron B. Kantor Ph.D. Chief Scientific Officer 2Immune Tolerance Institute Appoints Aaron B. Kantor Ph.D. Chief Scientific Officer 3Immune Tolerance Institute Appoints Aaron B. Kantor Ph.D. Chief Scientific Officer 4
(Date:3/12/2015)... , March 12, 2015 IriTech, a leading ... member of the Texas Instruments Design Network, announced today ... has demonstrated its IriShield USB MK2120U device during a ... for pension distribution. The iris scanner ... be marketed in India through ...
(Date:3/12/2015)... , March 12, 2015 WHEN:Tuesday, March ... Registration here: http://bit.ly/1G7Os0L . SPEAKERS: , Frost ... SeshagiriPhoto - http://photos.prnewswire.com/prnh/20150311/181111 Biometric ... to compete in several different markets and industries. ... currently witnessing an uptrend. Join ...
(Date:3/10/2015)... YORK , March 10, 2015  Continuing its ... the Unexpected, Hammacher Schlemmer introduces The Eye Scanning ... identity before granting access to secure websites or sensitive ... to verify travelers at international borders, the device has ... distinctive pattern points of the iris, converting them into ...
Breaking Biology News(10 mins):Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 3Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2
... 21, 2010 A group of researchers from Wake ... way to treat cancer by using lasers to light ... heat. Today at the 52nd Annual Meeting ... in Philadelphia, they will describe the latest development for ...
... protect oil imports coming from the Middle East are ... thought, new research from the University of Nebraska-Lincoln shows. ... to U.S. gasoline use but they should, the ... Perrin estimate that emissions of heat-trapping gases resulting from ...
... belly flops. But did you ever see a frog ... according to a new study1 by Dr. Richard Essner, ... colleagues, looking at the evolution of frog jumping and ... before they perfected landing. This evolutionary split, characterized by ...
Cached Biology News:Researchers use nanoparticles as destructive beacons to zap tumors 2Researchers: EPA should recognize environmental impact of protecting foreign oil 2Primitive frogs do a belly flop 2
GENOMIPHI V2 DNA AMP KIT 25RXN, 1 EA. Category: Genomics DNA Amplification....
EPH electrode, anode, 1. Category: Electrophoresis Systems & Standards & Reagents, IEF & SDS-PAGE & 2-D Electrophoresis, Multiphor II Kits & Components and Accessories....
... major advantages over other RNA precipitation methods in ... carbohydrates. It is the method of choice for ... RNA preparations. Note, LiCl precipitation may not remove ... the RNA is to be used for RT-PCR, ...
LIVE/DEAD® Cell-Mediated Cytotoxicity Kit *for animal cells* *2000 assays*...
Biology Products: